There hasn't been a peep out of Oxford Nanopore Technologies since the company announced in February that its DNA strand sequencing nanopore method is working and that it is developing it commercially. "When will nanopores actually hit the market?" asks Keith Robison at his Omics! Omics! blog.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Sewer Sequences

This Week in PLOS

Following the Curve

Sequencing to Go

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.